It is no secret that the incidence of diabetes is on the rise both in the United States and around the world. According to recent statistics, current trends estimate the prevalence of diabetes in the US will increase from 14% of the population to 33% by the year 2050.1 Between 15-25% of people with diabetes will develop foot and leg ulcers at some point.2 Diabetic foot ulcers are the leading cause of hospitalization among diabetic patients and often lead to amputations. An uncomplicated diabetic foot ulcer is estimated to cost $8000 to treat.3 Diabetes-related amputations cost approximately $3 billion dollars per year4 and approximately 85% of all lower extremity amputations are preceded by a diabetic ulcer. 5 Simply put, diabetic wounds cost the US health care system billions of dollars each year.
Management of these wounds is of the utmost importance, both in terms of patient quality of life and cost containment. CellerateRX® is a patented form of collagen that has been shown to be effective in managing diabetic wounds in multiple clinical applications and settings. In one evidence based study at a major wound care center in the northeast, the CellerateRX® treated wounds were healed by five (5) weeks while the control wound were approximately 80% healed at twelve (12) weeks. 1 These results were accomplished with once or twice a week application. This is significant both in terms of patient compliance and cost containment.
CellerateRX® powder and gel form allows for no waste of product and is biocompatible and may used with any secondary dressing. It is biodegradable and does not need to be removed from the wound with subsequent dressing applications which is important as it provides:
The powder and gel are ideal for tunneled/undermining wounds and skin flaps or tears.
CellerateRX® provides for quality outcomes in a cost effective manner. Cost containment measures include:
Its ease of application makes it ideal for home health or for those patients who take care of their own wounds as noted by Rhonda Surgnier who said, "My mother had a venous stasis ulcer on her inner ankle for over a year that we aggressively treated in order to heal. We used a variety of treatments including wet to dry, Silvadene®, Unna Boot and DuoDerm® dressings, none of which made any improvement. We began using the CellerateRX® and within a month the ulcer had almost completely healed. The advantages of the CellerateRX®, in addition to healing the ulcer, it provided pain relief and decreased our dressing supply cost. The product was so easy to use that she was able to perform her own wound dressings. The results that the CellerateRX® produced in such a short period of time were amazing."
© 2011 All Rights Reserved, Wound Care Innovations, LLC - A Wound Management Technologies, Inc. Company
